Weak U.S. dollar should boost Big Pharma earnings Major pharmaceutical companies are expected to roll out higher second-quarter earnings reports next week, helped partly by strong overseas sales stoked by a weak U.S.dollar.Some of the sector's heaviest hitters will be on deck next week,...
Dollar boost for pharma Some of the sector's heaviest hitters will be on deck next week, including Merck & Co.(MRK:MRKNews, chart, profile, moreLast: Delayed quote dataAnalyst Create alertInsiderDiscussFinancials Sponsored by:, , ) , Schering-Plough Corp.
...
Earnings Outlook: Weak U.S. dollar should boost Big Pharma earnings Some of the sector's heaviest hitters will be on deck next week, including Merck & Co.(MRK:MRKNews, chart, profile, moreLast: Delayed quote dataAnalyst Create alertInsiderDiscussFinancials Sponsored by:, , ) , Schering-Plough Corp.
...
Earnings Preview: Merck & Co WHITEHOUSE STATION, N.J.Merck & Co., the world's No.8 drugmaker by sales, reports earnings for the second quarter on Monday morning.
The following is a summary of key developments and analyst opinion related to the period.OVERVIEW:...
Earnings Preview: Merck & Co. [XFNA] WHITEHOUSE STATION, N.J.(AP) - Merck & Co., the world's No.
8 drugmaker by sales, reports earnings for the second quarter on Monday morning.
The following is a summary of key developments and analyst opinion related to the...
Earnings Preview: Merck & Co before market open, with a conference call scheduled for 9:00 am ET.Analysts are looking for a profit of 83c on revenue of $6.05B.
The consensus range is 80c to 85c for EPS, and revenue of $5.86B to $6.19B, according to First Call.
In...
Amid setbacks with FDA, Merck settles bulk of its Vioxx lawsuits, trims sales force - 5:38 p.m.WHITEHOUSE STATION, N.J.
(AP) - Merck & Co., the world's No.
8 drugmaker by sales, reports earnings for the second quarter on Monday morning.
The following is a summary of key developments and analyst opinion related...
Amid restructuring, Organon buy, drugs awaiting approval boost Schering-Plough sales KENILWORTH, N.J.(AP) - Schering-Plough Corp., a major drug and consumer health products maker, reports earnings for the second quarter on Monday morning.
The following is a summary of key developments and analyst opinion related to the...
Foolish Forecast: How Quickly Can Merck Turn It Around? Merck (NYSE: MRK) has had a string of tough breaks this year.We'll get a closer look at whether its turnaround is imminent when it releases earnings on the other side of the weekend, but until then, here's a preview of what to expect.
Amid restructuring, Organon buy, drugs awaiting approval boost Schering - Plough sales Amid restructuring, Organon buy, drugs awaiting approval boost Schering-Plough sales KENILWORTH, N.J.(AP) - Schering-Plough Corp., a major drug and consumer health products maker, reports earnings for the second quarter on Monday morning....
Ahead of the Bell: Schering-Plough inches up NEW YORK Schering-Plough Corp.shares edged up Tuesday after a Lehman Brothers analyst raised his rating to 'Buy,' saying the drug maker will post better profit and revenue growth than its rivals through 2012.
Charles Butler upgraded the...
Ahead of the Bell: Schering-Plough inches up NEW YORK - Schering-Plough Corp.shares edged up Tuesday after a Lehman Brothers analyst raised his rating to 'Buy,' saying the drug maker will post better profit and revenue growth than its rivals through 2012.
Charles Butler upgraded...
Ahead of the Bell: Schering-Plough inches up NEW YORK (AP) -- Schering-Plough Corp.shares edged up Tuesday after a Lehman Brothers analyst raised his rating to 'Buy,' saying the drug maker will post better profit and revenue growth than its rivals through 2012.
Charles Butler...
UPDATE 1-RESEARCH ALERT-Lehman upgrades Schering-Plough July 15 - Lehman Brothers upgraded Schering-Plough Corp (SGP.N: Quote, Profile, Research, Stock Buzz) to 'overweight' from 'equal-weight', based on an improved sales outlook for cholesterol drugs Vytorin and Zetia. The drug maker is...
A Drug to Fertilize Schering-Plough's Growth? Down 20% so far this year, Schering-Plough (NYSE: SGP) needs something to replace all those cholesterol-fighting Vytorin and Zetia prescriptions (and revenue) that it and Merck (NYSE: MRK) are expected to lose.Yesterday, the company...
The Vytorin Stretch Does a failed trial of Pfizer's cholesterol-lowering pill Lipitor make the rival drug Vytorin look better by comparison?No, say several top cardiologists?
But exactly that prospect has generated excitement from one Wall Street analyst...
Lipitor Study Means Little For Vytorin, Say Cardiologists Does a failed trial of Pfizer's cholesterol-lowering pill Lipitor make the rival drug Vytorin look better by comparison?No, say several top cardiologists?
But exactly that prospect has generated excitement from one Wall Street analyst...
CASHMERE: No IMT effect with atorvastatin over 12 months New York, NY - A small but intriguing clinical trial has shown that atorvastatin (Lipitor, Pfizer) was no more effective than placebo in slowing the progression of atherosclerosis [1].Over the course of the 12-month study, investigators...
A Drug to Fertilize Schering-Plough's Growth? Down 20% so far this year, Schering-Plough (NYSE: SGP) needs something to replace all those cholesterol-fighting Vytorin and Zetia prescriptions (and revenue) that it and Merck (NYSE: MRK) are expected to lose.Yesterday, the company...
UBS: Guarded Outlook for Merck's Gardasil Shares of Merck (MRK), which have lost more than a third of their value so far this year, were under continued pressure yesterday.They were at 60 bucks in early January.
Today they're trading around $37.
Big pharma analyst Rupesh...
Merck falls as analyst forecasts weaker profits NEW YORK Shares of Merck & Co.declined Monday after a UBS analyst downgraded the drug maker, saying sales of its HPV treatment Gardasil may disappoint, and shortages of other vaccines will limit Merck's profit.
Roopesh Patel...
Merck falls as analyst forecasts weaker profits Shares of Merck & Co.declined Monday after a UBS analyst downgraded the drug maker, saying sales of its HPV treatment Gardasil may disappoint, and shortages of other vaccines will limit Merck's profit.
Roopesh Patel downgraded the...
Merck falls as analyst forecasts weaker profits Roopesh Patel downgraded the stock to 'Neutral' from 'Buy,' and trimmed his price target to $40 per share from $43.He said data from IMS Health shows sales of Gardasil slowed to about $300 million in the second quarter -- about $50...
Merck falls as analyst forecasts weaker profits NEW YORK (AP) -- Shares of Merck & Co.declined Monday after a UBS analyst downgraded the drug maker, saying sales of its HPV treatment Gardasil may disappoint, and shortages of other vaccines will limit Merck's profit.
Roopesh Patel...
Merck slips; Analyst: Weak Gardasil and manufacturing problems will cut profits Merck sells Vytorin and Zetia through a joint venture with Schering-Plough Corp.Earlier this year, a clinical study showed the drug was no more effective than generic drug versions of an older drug, Zocor, at preventing the buildup...
